New antibody injection tested to control rare blood cancers
NCT ID NCT04239157
Summary
This study is testing whether a medication called canakinumab, given as a monthly injection, can help control certain low-risk blood and bone marrow disorders. It aims to see if the treatment improves blood counts, reduces the need for blood transfusions, and is safe for patients. The trial is for adults with specific types of myelodysplastic syndrome or chronic myelomonocytic leukemia who have not responded well to prior standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.